Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Allurion Technologies (NYSE: ALUR) shares are moving higher Friday potentially after after the company announced plans to ...

NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a company focused on obesity treatment solutions, has expanded its ...

Anduril, the closely held technology startup that makes autonomous systems and weapons for the military, on Thursday announced plans to build a $1 billion factory in Columbus, Ohio. The company ...

Space Perspective, the Titusville balloon-tourism company that hopes to someday lift passengers 100,000 feet above Earth inside luxurious pressurized capsules, owes $90,295 in unpaid base rent for ...

Allurion Technologies shares rose after agreeing to a private placement with expected gross proceeds of $2.5 million that will extend its runway through early 2026. The stock was up 13% to $3.37 ...

Our 2025 plan includes scaling our new commercial strategy, advancing the Allurion Balloon through the FDA approval process, setting the company up for a profitable 2026, expanding our digital ...

Our 2025 plan includes scaling our new commercial strategy, advancing the Allurion Balloon through the FDA approval process, setting the company up for a profitable 2026, expanding our digital ...